Gaelic Laboratories and Athlone Laboratories have aligned their manufacturing processes to offer customers a dual-source supply of oral beta-lactam antibiotics from two Irish production sites following Gaelic’s acquisition of Athlone in December 2025.
The companies will launch the supply strategy at CPHI Milan, scheduled for Oct. 6-8, 2026. The approach is intended to reduce customers’ reliance on a single manufacturing location. Together, the facilities have capacity to produce 1.2 billion oral dosage forms annually.
Gaelic and Athlone are good manufacturing practice-approved producers of beta-lactam antibiotics, a broad class that includes penicillin-related medicines. Their products are supplied in Ireland, the U.K., the European Union, the Middle East and North Africa, Canada and Australia.
The companies said the integration program has focused on restructuring manufacturing work across the sites, consolidating supply chains and standardizing processes to allow products to be made at either location under the same processes and quality standards.
The first phase of the integration was completed earlier this year. It included operational changes, supply-chain consolidation, an internal communications program and a joint website. The companies said the current phase centers on aligning manufacturing operations and technology-transfer protocols to support the dual-source model.
Brian Morrissey, general manager, said both sites are undergoing technology and expansion investments. The companies are also upgrading the facilities to comply with the latest Antimicrobial Resistance Industry Alliance Manufacturing Standard, according to the release.
The two-site approach is designed to provide customers with manufacturing redundancy within the European Union and reduce supply risks if one location faces a production disruption.